Publikation

Management of patients with castration-resistant disease

Wissenschaftlicher Artikel/Review - 20.09.2013

Bereiche
PubMed
DOI

Zitation
Pezaro C, Omlin A, Lorente D, de Bono J. Management of patients with castration-resistant disease. Hematol Oncol Clin North Am 2013; 27:1243-60, ix.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Hematol Oncol Clin North Am 2013; 27
Veröffentlichungsdatum
20.09.2013
eISSN (Online)
1558-1977
Seiten
1243-60, ix
Kurzbeschreibung/Zielsetzung

The medical management of men with castration-resistant prostate cancer (CRPC) has changed dramatically in the last decade. Men can now access several agents developed to extend survival, delay morbidity caused by complications, and preserve quality of life. Strategies to extend survival include docetaxel and cabazitaxel, the CYP-inhibitor abiraterone acetate, the second-generation androgen receptor antagonist enzalutamide, sipuleucel-T immunotherapy, and the α-emitting radionuclide (223)radium. These novel therapies have fostered interest in translational science and a deeper understanding of the underlying biology of CRPC. This article summarizes clinical data and unresolved issues in the use of current and emerging CRPC therapies.